Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis

Journal of Immunology

Volumn 163, Issue 3, 1999, Pages 1521-1528

  Charles, Peter ^a   Elliott, Michael J ^b   Davis, Diana ^b   Potter, Alison ^b   Kalden, Joachim R ^c   Antoni, Christian ^c   Breedveld, Ferdinand C ^d   Smolen, Josef S ^e   Eberl, Gabriele ^c   De Woody, Kim ^f   Feldmann, Marc ^b   Maini, Ravinder N ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ACUTE-PHASE PROTEINS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; LONGITUDINAL STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033179534     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.
2. Brennan, F. M., C. O. C. Zachariae, D. Chantry, C. G. Larsen, M. Turner, R. N. Maini, K. Matsushima, and M. Feldmann. 1990. Detection of interleukin-8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of IL-8 mRNA by isolated synovial cells. Eur. J. Immunol. 31:293.
3. Husby, G., and R. C. Williams Jr. 1988. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J. Autoimmun. 1:363.
4. Chu, C. Q., M. Field, M. Feldmann, and R. N. Maini. 1991. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34:1125.
5. Saxne, T., M. A. Palladino Jr, D. Heinegard, N. Talal, and F. A. Wollheim. 1988. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31:1041.
6. Tetta, C., G. Camussi, V. Modena, C. Di Vittorio, and C. Baglioni. 1990. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann. Rheum. Dis. 49:665.
7. Cope, A. P., D. Aderka, M. Doherty, H. Englemann, D. Gibbons, A. C. Jones, F. M. Brennan, R. N. Maini, D. Wallach, and M. Feldmann. 1992. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35:1160.
8. Buchan, G., K. Barrett, M. Turner, D. Chantry, R. N. Maini, and M. Feldmann. 1988. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin. Exp. Immunol. 73:449.
9. Brennan, F. M., D. Chantry, A. Jackson, R. Maini, and M. Feldmann. 1989. Inhibitory effects of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet ii:244.
10. Haworth, C., F. M. Brennan, D. Chantry, M. Turner, R. N. Maini, and M. Feldmann. 1991. Expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumour necrosis factor α. Eur. J. Immunol. 21:2575.
11. Butler, D. M., R. N. Maini, M. Feldmann, and F. M. Brennan. 1995. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti-TNFα antibody with the IL-1 receptor antagonist. Eur. Cytokine Network 6:225.
12. Williams, R. O., M. Feldmann, and R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89:9784.
13. Thorbecke, G. J., R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino. 1992. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89:7375.
14. Wooley, P. H., J. Dutcher, M. B. Widmer, and S. Gillis. 1993. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151:6602.
15. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025.
16. Probert, L., D. Plows, G. Kontogeorgos, and G. Kollias. 1995. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur. J. Immunol. 25:1794.
17. Feldmann, M., F. M. Brennan, D. Chantry, C. Haworth, M. Turner, E. Abney, G. Buchan, K. Barrett, D. Barkley, and R. N. Maini. 1990. Cytokine production in the rheumatoid joint: implications for treatment. Ann. Rheum. Dis. 49:480.
18. Brennan, F. M., R. N. Maini, and M. Feldmann. 1992. TNFα - A pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31:293.
19. Elliott, M. J., R. N. Maini, M. Feldmann, A. Long-Fox, P. Charles, P. Katsikis, F. M. Brennan, J. Walker, H. Bijl, J. Ghrayeb, and J. N. Woody. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36:1681.
20. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, and J. N. Woody. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105.
21. Elliott, M. J., R. N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Bijl, and J. N. Woody. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125.
22. Paleolog, E. M., S.-A. J. Delasalle, W. A. Buurman, and M. Feldmann. 1994. Functional activities of receptors for tumor necrosis factor-α on human vascular endothelial cells. Blood 84:2578.
23. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, T. A. Medsger, Jr., D. M. Mitchell, D. H. Neustadt, R. S. Pinals, J. G. Schaller, J. T. Sharp, R. L. Wilder, and G. G. Hunder. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315.
24. Knight, D. M., H. Trinh, J. Le, S. Siegel, D. Shealy, M. McDonough, B. Scallon, A. M. Moore, J. Vilcek, P. Daddona, and J. Ghrayeb. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30:1443.
25. Leeuwenberg, J. F. M., E. F. Smeets, J. J. Neefjes, M. A. Shaffer, T. Cinek, T. M. A. A. Jeunhomme, and W. A. Buurman. 1992. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543.
26. Holt, I., R. G. Cooper, J. Denton, A. Meager, and S. J. Hopkins. 1992. Cytokine inter-relationships and their association with disease activity in arthritis. Br. J. Rheumatol. 31:725.
27. Lapadula, G., F. Iannone, F. Dell'Accio, M. Covelli, and V. Popitone. 1995. Interleukin 10 in rheumatoid arthritis. Clin. Exp. Rheumatol. 13:629.
28. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA 84:7251.
29. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today 15:74.
30. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bleuthmann, and G. Kohler. 1994. Impaired immune and acute-phase response in interleukin 6 deficient mice. Nature 368:339.
31. Feldmann, M., M. J. Elliott, J. N. Woody, and R. N. Maini. 1997. Anti-tumor necrosis factor-α therapy in rheumatoid arthritis. Adv. Immunol. 64:283.
32. Wendling, D., E. Racadot, and J. Wijdenes. 1993. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20:259.
33. Lu, Z. Y., J. Brochier, J. Wijdenes, H. Brailly, R. Bataille, and B. Klein. 1992. High amounts of circulating interleukin (IL-6) in the form of monomeric immune complexes during antioIL-6 therapy: towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22:2819.
34. Arend, W. P., and J.-M. Dayer. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38:151.
35. Firestein, G. S., and N. J. Zvaifler. 1987. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that γ-interferon is not the primary macrophage activating factor. Arthritis Rheum 30:864.
36. Deleuran, B. W., C. Q. Chu, M. Field, F. M. Brennan, P. Katsikis, M. Feldmann, and R. N. Maini. 1992. Localization of interleukin-1α, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br. J. Rheumatol. 31:801.
37. Chu, C. Q., M. Field, S. Allard, E. Abney, M. Feldmann, and R. N. Maini. 1992. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31:653.
38. Barkley, D. E. H., M. Feldmann, and R. N. Maini. 1990. Cells with dendritic morphology and bright interleukin-1α staining circulate in the blood of patients with rheumatoid arthritis. Clin. Exp. Immunol. 80:25.
39. Goto, M., M. Fujisawa, A. Yamada, T. Okabe, F. Takaku, M. Sasano, and K. Nishioka. 1990. Spontaneous release of angiotensin converting enzyme and interleukin 1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann. Rheum. Dis. 49:172.
40. Lorenz, H. M., C. Antoni, T. Valerius, R. Repp, M. Grunke, N. Schwerdtner, H. Nusslein, J. Woody, J. R. Kalden, and B. Manger. 1996. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J. Immunol. 156:1646.
41. Arend, W. P. 1993. Interleukin-1 receptor antagonist. Adv. Immunol. 54:167.
42. Van der Poll, J., S. J. van Deventer, and H. ten Cate. 1994. Tumor necrosis factor is involved in the appearance of endotoxemia. J. Infect. Dis. 169:665.
43. Houssiau, F. A., J. Devogelaer, J. van Damme, C. N. de Deuxchaisnes, and J. van Snick. 1988. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31:784.
44. Swaak, A. J., A. Van Rooyen, E. Nieuwenhuis, and L. A. Aarden. 1988. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand. J. Rheumatol. 17:469.
45. Arvidson, N. G., B. Gudbjörnsson, L. Elfman, A.-C. Ryden, T. H. Tötterman, and R. Hällgren. 1994. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann. Rheum. Dis. 53:521.
46. Hirano, T., T. Matsuda, M. Turner, N. Miyasaka, G. Buchan, B. Tang, K. Sato, M. Shimizu, R. Maini, M. Feldmann, and T. Kishimoto. 1988. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18:1797.
47. Van Dullemen, H. M., S. J. H. Van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. J. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129.
48. Castell, I. V., T. Geiger, V. Gross, T. Andus, E. Walter, T. Hirano, T. Kishimoto, and P. C. Heinrich. 1988. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 177:357.
49. Vischer, T. L., C. F. Werner-Favre, L. Wen, and R. H. Zubler. 1988. Quantitave analysis of precursors requency of rheumatoid factor (RF) producing human B cells. Scand. J. Rheumatol. 75:123.
50. Husby, G. 1992. Amyloidosis. Semin. Arthritis Rheum. 22:67.
51. Liuzzo, G., L. M. Biasucchi, J. R. Gallimore, R. L. Grillo, A. G. Rebuzzi, M. B. Pepys, and A. Maseri. 1994. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331:417.
52. Meade, T. W. 1995. Fibrinogen in ischaemic heart disease. Eur. Heart J. 16 Suppl. A:31.
53. Brown, A. S., and J. F. Martin. 1994. The megakaryocyte platelet system and vascular disease. Eur. J. Clin. Invest. 24 Suppl. 1:9.